IBDEI0MU ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10430,1,4,0)
 ;;=4^M81.0
 ;;^UTILITY(U,$J,358.3,10430,2)
 ;;=^5013555
 ;;^UTILITY(U,$J,358.3,10431,0)
 ;;=M85.80^^68^667^44
 ;;^UTILITY(U,$J,358.3,10431,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10431,1,3,0)
 ;;=3^Osteopenia,Unspec Site
 ;;^UTILITY(U,$J,358.3,10431,1,4,0)
 ;;=4^M85.80
 ;;^UTILITY(U,$J,358.3,10431,2)
 ;;=^5014473
 ;;^UTILITY(U,$J,358.3,10432,0)
 ;;=N62.^^68^667^24
 ;;^UTILITY(U,$J,358.3,10432,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10432,1,3,0)
 ;;=3^Gynecomastia
 ;;^UTILITY(U,$J,358.3,10432,1,4,0)
 ;;=4^N62.
 ;;^UTILITY(U,$J,358.3,10432,2)
 ;;=^5015790
 ;;^UTILITY(U,$J,358.3,10433,0)
 ;;=E10.43^^68^667^6
 ;;^UTILITY(U,$J,358.3,10433,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10433,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Autonomic Polyneuropathy
 ;;^UTILITY(U,$J,358.3,10433,1,4,0)
 ;;=4^E10.43
 ;;^UTILITY(U,$J,358.3,10433,2)
 ;;=^5002607
 ;;^UTILITY(U,$J,358.3,10434,0)
 ;;=E10.59^^68^667^4
 ;;^UTILITY(U,$J,358.3,10434,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10434,1,3,0)
 ;;=3^DM Type 1 w/ Circulatory Complications
 ;;^UTILITY(U,$J,358.3,10434,1,4,0)
 ;;=4^E10.59
 ;;^UTILITY(U,$J,358.3,10434,2)
 ;;=^5002612
 ;;^UTILITY(U,$J,358.3,10435,0)
 ;;=E10.618^^68^667^5
 ;;^UTILITY(U,$J,358.3,10435,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10435,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Arthropathy
 ;;^UTILITY(U,$J,358.3,10435,1,4,0)
 ;;=4^E10.618
 ;;^UTILITY(U,$J,358.3,10435,2)
 ;;=^5002614
 ;;^UTILITY(U,$J,358.3,10436,0)
 ;;=E10.621^^68^667^7
 ;;^UTILITY(U,$J,358.3,10436,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10436,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Foot Ulcer
 ;;^UTILITY(U,$J,358.3,10436,1,4,0)
 ;;=4^E10.621
 ;;^UTILITY(U,$J,358.3,10436,2)
 ;;=^5002616
 ;;^UTILITY(U,$J,358.3,10437,0)
 ;;=E10.622^^68^667^11
 ;;^UTILITY(U,$J,358.3,10437,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10437,1,3,0)
 ;;=3^DM Type 1 w/ Skin Ulcer
 ;;^UTILITY(U,$J,358.3,10437,1,4,0)
 ;;=4^E10.622
 ;;^UTILITY(U,$J,358.3,10437,2)
 ;;=^5002617
 ;;^UTILITY(U,$J,358.3,10438,0)
 ;;=E10.65^^68^667^10
 ;;^UTILITY(U,$J,358.3,10438,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10438,1,3,0)
 ;;=3^DM Type 1 w/ Hyperglycermia
 ;;^UTILITY(U,$J,358.3,10438,1,4,0)
 ;;=4^E10.65
 ;;^UTILITY(U,$J,358.3,10438,2)
 ;;=^5002623
 ;;^UTILITY(U,$J,358.3,10439,0)
 ;;=E10.39^^68^667^9
 ;;^UTILITY(U,$J,358.3,10439,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10439,1,3,0)
 ;;=3^DM Type 1 w/ Diabetic Ophthalmic Complications NEC
 ;;^UTILITY(U,$J,358.3,10439,1,4,0)
 ;;=4^E10.39
 ;;^UTILITY(U,$J,358.3,10439,2)
 ;;=^5002603
 ;;^UTILITY(U,$J,358.3,10440,0)
 ;;=E66.3^^68^667^45
 ;;^UTILITY(U,$J,358.3,10440,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10440,1,3,0)
 ;;=3^Overweight
 ;;^UTILITY(U,$J,358.3,10440,1,4,0)
 ;;=4^E66.3
 ;;^UTILITY(U,$J,358.3,10440,2)
 ;;=^5002830
 ;;^UTILITY(U,$J,358.3,10441,0)
 ;;=E89.1^^68^667^49
 ;;^UTILITY(U,$J,358.3,10441,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10441,1,3,0)
 ;;=3^Postprocedural Hypoinsulinemia
 ;;^UTILITY(U,$J,358.3,10441,1,4,0)
 ;;=4^E89.1
 ;;^UTILITY(U,$J,358.3,10441,2)
 ;;=^5003036
 ;;^UTILITY(U,$J,358.3,10442,0)
 ;;=H40.9^^68^668^9
 ;;^UTILITY(U,$J,358.3,10442,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10442,1,3,0)
 ;;=3^Glaucoma,Unspec
 ;;^UTILITY(U,$J,358.3,10442,1,4,0)
 ;;=4^H40.9
 ;;^UTILITY(U,$J,358.3,10442,2)
 ;;=^5005931
 ;;^UTILITY(U,$J,358.3,10443,0)
 ;;=H26.9^^68^668^5
 ;;^UTILITY(U,$J,358.3,10443,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10443,1,3,0)
 ;;=3^Cataract,Unspec
 ;;^UTILITY(U,$J,358.3,10443,1,4,0)
 ;;=4^H26.9
 ;;^UTILITY(U,$J,358.3,10443,2)
 ;;=^5005363
